NCT00006436 2025-12-30
EPOCH and Rituximab to Treat Non-Hodgkin's Lymphoma in Patients With HIV Infection
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
Clinical Trials
44 trialsNCT00924027 2025-09-05
A Study of Patients Receiving High-Dose Rate Brachytherapy
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT01295944 2025-08-05
Carboplatin and Bevacizumab for Recurrent Ependymoma
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT04852302 2025-05-31
Managing Cancer and Living Meaningfully (CALM) Therapy in Individuals Diagnosed With a Primary Brain Tumor
National Institutes of Health Clinical Center (CC)
Phase NA Completed
NCT02595866 2024-08-09
Testing the Addition of an Experimental Medication MK-3475 (Pembrolizumab) to Usual Anti-Retroviral Medications in Patients With HIV and Cancer
National Cancer Institute (NCI)
Phase 1 Completed
NCT03206073 2023-10-24
A Phase I/II Study of Pexa-Vec Oncolytic Virus in Combination With Immune Checkpoint Inhibition in Refractory Colorectal Cancer
National Institutes of Health Clinical Center (CC)
Phase 1/2 Completed
NCT01468922 2022-07-01
Pazopanib and ARQ 197 for Advanced Solid Tumors
National Institutes of Health Clinical Center (CC)
Phase 1 Completed
NCT02810418 2022-03-15
Mesothelin-Targeted Immunotoxin LMB-100 Alone or in Combination With Nab-Paclitaxel in People With Previously Treated Metastatic and/or Locally Advanced Pancreatic Ductal Adenocarcinoma and Mesothelin Expressing Solid Tumors
National Institutes of Health Clinical Center (CC)
Phase 1/2 Completed
NCT02496676 2022-03-02
Magnesium Supplementation in People With XMEN Syndrome
National Institutes of Health Clinical Center (CC)
Phase 1/2 Completed
NCT02723864 2022-02-08
Veliparib (ABT-888), an Oral PARP Inhibitor, and VX-970, an ATR Inhibitor, in Combination With Cisplatin in People With Refractory Solid Tumors
National Institutes of Health Clinical Center (CC)
Phase 1 Completed
NCT00038727 2021-12-28
DPPOS
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Phase 3 Unknown
NCT00001880 2021-11-10
Stem Cell Transplantation for Metastatic Solid Tumors
National Institutes of Health Clinical Center (CC)
Phase 2 Terminated
NCT02179515 2021-01-26
Safety and Tolerability of a Modified Vaccinia Ankara (MVA)-Based Vaccine Modified to Express Brachyury and T-cell Costimulatory Molecules (MVA-Brachyury-TRICOM)
National Institutes of Health Clinical Center (CC)
Phase 1 Completed
NCT03789175 2020-12-08
Nicotinamide Riboside on Mitochondrial Function in Li-Fraumeni Syndrome
National Institutes of Health Clinical Center (CC)
Phase 1/2 Completed
NCT02315625 2020-09-09
Study of Mutation-Targeted Therapy With Sunitinib or Everolimus in People With Advanced Low- or Intermediate-Grade Neuroendocrine Tumors of the Gastrointestinal Tract and Pancreas With or Without Cytoreductive Surgery
National Institutes of Health Clinical Center (CC)
Phase 2 Terminated
NCT01479348 2020-06-02
Imaging Study for FdCyd and THU Cancer Treatment
National Institutes of Health Clinical Center (CC)
Phase EARLY_PHASE1 Terminated
NCT00478140 2019-08-20
Trastuzumab in Treating Patients With Locally Advanced or Metastatic Gallbladder Cancer or Bile Duct Cancer That Cannot Be Removed by Surgery
National Cancer Institute (NCI)
Phase 2 Terminated
NCT00214422 2019-07-19
Intensity Modulated Radiation Therapy for Prostate Cancer
National Institutes of Health Clinical Center (CC)
Phase EARLY_PHASE1 Completed
NCT00088413 2019-04-16
PANVAC-V and PANVAC-F Vaccines Plus Sargramostim to Treat Advanced Cancer
National Institutes of Health Clinical Center (CC)
Phase 1/2 Completed
NCT01273155 2019-03-26
Belinostat for Solid Tumors and Lymphomas in Patients With Varying Degrees of Hepatic Dysfunction
National Institutes of Health Clinical Center (CC)
Phase 1 Completed
NCT00923247 2018-11-29
A Targeted Phase I/II Trial of ZD6474 (Vandetanib; ZACTIMA) Plus the Proteasome Inhibitor, Bortezomib (Velcade ), in Adults With Solid Tumors With a Focus on Hereditary or Sporadic, Locally Advanced or Metastatic Medullary Thyroid Cancer (MTC)
National Institutes of Health Clinical Center (CC)
Phase 1/2 Terminated
NCT00923351 2018-06-15
Therapy to Treat Ewing's Sarcoma, Rhabdomyosarcoma or Neuroblastoma
National Institutes of Health Clinical Center (CC)
Phase 1/2 Completed
NCT00089609 2018-04-20
Docetaxel, Thalidomide, Prednisone, and Bevacizumab to Treat Metastatic Prostate Cancer
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT02192541 2018-03-29
Ganetespib and Ziv-Aflibercept in Refractory Gastrointestinal Carcinomas, Non-Squamous Non-Small Cell Lung Carcinomas, Urothelial Carcinomas, and Sarcomas
National Institutes of Health Clinical Center (CC)
Phase 1 Terminated
NCT00080535 2018-01-29
Anti-Tac(Fv)-PE38 (LMB-2) to Treat Cutaneous T-Cell Lymphomas
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT01519817 2018-01-29
Cancer Vaccine Targeting Brachyury Protein in Tumors
National Institutes of Health Clinical Center (CC)
Phase 1 Completed
NCT00077922 2018-01-23
Anti-Tac(Fv)-PE38 (LMB-2) to Treat Chronic Lymphocytic Leukemia
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT01287013 2018-01-05
Comparing Xperguide vs. Conventional Methods During Percutaneous Image Guided Procedures
National Institutes of Health Clinical Center (CC)
Phase NA Terminated
NCT00031551 2017-12-06
Evaluation of Efficacy and Mechanisms of an Antiinflammatory Intervention for Chemotherapy Related Mucosal Injury
National Institutes of Health Clinical Center (CC)
Phase 2 Terminated
NCT00055237 2017-09-06
Bevacizumab to Treat Kaposi's Sarcoma in HIV-Positive and HIV-Negative Patients
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT00082368 2017-08-17
PET Imaging With Tc-94m Sestamibi to Assess Resistance to Chemotherapy
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT01271907 2017-08-01
Drosophila-generated CTL
National Institutes of Health Clinical Center (CC)
Phase 2 Terminated
NCT01174264 2017-05-19
Evaluation of Food Effect on Pharmacokinetics of Vismodegib
National Cancer Institute (NCI)
Phase 1/2 Completed
NCT00108069 2015-11-05
Tamoxifen and Bortezomib to Treat Recurrent Brain Tumors
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT00924287 2015-10-28
Gene Therapy Using Anti-Her-2 Cells to Treat Metastatic Cancer
National Institutes of Health Clinical Center (CC)
Phase 1/2 Terminated
NCT01372813 2015-10-23
Vandetanib to Treat Advanced Kidney Cancer
National Institutes of Health Clinical Center (CC)
Phase 2 Terminated
NCT00365274 2014-06-02
SGN-30 and Combination Chemotherapy in Treating Patients With Newly Diagnosed Anaplastic Large Cell Lymphoma
National Cancer Institute (NCI)
Phase 2 Terminated
NCT00290472 2014-05-23
CCI-779 in Treating Patients With Recurrent or Refractory B-Cell Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia
National Cancer Institute (NCI)
Phase 2 Completed
NCT00492089 2014-05-09
Bevacizumab in Reducing CNS Side Effects in Patients Who Have Undergone Radiation Therapy to the Brain for Primary Brain Tumor, Meningioma, or Head and Neck Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00513604 2013-06-03
Phase II Study of Short-Term Cultured Anti-Tumor Autologous Lymphocytes After Lymphocyte-Depleting Chemotherapy in Metastatic Melanoma
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT00924001 2012-10-25
Chemotherapy Followed by Infusion of DMF5 Cells to Treat Metastatic Melanoma
National Institutes of Health Clinical Center (CC)
Phase 1/2 Terminated
NCT00972205 2012-07-19
Paclitaxel and CBT-1(Registered Trademark) to Treat Solid Tumors
National Institutes of Health Clinical Center (CC)
Phase NA Completed
NCT00098254 2012-05-02
BAY 43-9006 (Sorafenib) to Treat Relapsed Non-Small Cell Lung Cancer
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT00393029 2011-08-15
Phase II Study of Metastatic Cancer That Overexpresses P53 Using Lymphodepleting Conditioning Followed by Infusion of Anti-P53 TCR-Gene Engineered Lymphocytes
National Institutes of Health Clinical Center (CC)
Phase 2 Completed